124 related articles for article (PubMed ID: 20687215)
21. Over expression of ID-1 in prostate cancer.
Ouyang XS; Wang X; Lee DT; Tsao SW; Wong YC
J Urol; 2002 Jun; 167(6):2598-602. PubMed ID: 11992094
[TBL] [Abstract][Full Text] [Related]
22. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
[TBL] [Abstract][Full Text] [Related]
23. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
24. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer.
Eastham JA; Truong LD; Rogers E; Kattan M; Flanders KC; Scardino PT; Thompson TC
Lab Invest; 1995 Nov; 73(5):628-35. PubMed ID: 7474936
[TBL] [Abstract][Full Text] [Related]
25. [Expression and significance of clusterin in normal prostate, benign prostate hyperplasia and prostate cancer].
Zhou LQ; Yang XZ; Zeng L; Liang LL; Yang XY; Ren L; Chung L; Zhang ZW; Na YQ; Gu FL; Guo YL
Zhonghua Wai Ke Za Zhi; 2003 Feb; 41(2):93-5. PubMed ID: 12783666
[TBL] [Abstract][Full Text] [Related]
26. Thrombin receptor expression is upregulated in prostate cancer.
Kaushal V; Kohli M; Dennis RA; Siegel ER; Chiles WW; Mukunyadzi P
Prostate; 2006 Feb; 66(3):273-82. PubMed ID: 16245281
[TBL] [Abstract][Full Text] [Related]
27. Activator protein 2alpha transcription factor expression is associated with luminal differentiation and is lost in prostate cancer.
Ruiz M; Troncoso P; Bruns C; Bar-Eli M
Clin Cancer Res; 2001 Dec; 7(12):4086-95. PubMed ID: 11751506
[TBL] [Abstract][Full Text] [Related]
28. Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins.
Tang DG; Li L; Chopra DP; Porter AT
Cancer Res; 1998 Aug; 58(15):3466-79. PubMed ID: 9699682
[TBL] [Abstract][Full Text] [Related]
29. [Expressions of endothelin-1 in benign prostatic hyperplasia and prostate cancer and their significance].
Zhou WQ; Sun YH; Yin HL; Zhang ZY; Ge JP; Cheng W; Ma HQ; Wei W; Zhou SG; Ma HH; Gao JP
Zhonghua Nan Ke Xue; 2007 Aug; 13(8):685-9. PubMed ID: 17918704
[TBL] [Abstract][Full Text] [Related]
30. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study.
Sasor A; Wagrowska-Danilewicz M; Danilewicz M
Pol J Pathol; 2000; 51(1):31-6. PubMed ID: 10833901
[TBL] [Abstract][Full Text] [Related]
31. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
Kirchhofer D; Peek M; Lipari MT; Billeci K; Fan B; Moran P
FEBS Lett; 2005 Mar; 579(9):1945-50. PubMed ID: 15792801
[TBL] [Abstract][Full Text] [Related]
32. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma.
Kataoka H; Hamasuna R; Itoh H; Kitamura N; Koono M
Cancer Res; 2000 Nov; 60(21):6148-59. PubMed ID: 11085539
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia.
Hu XY; Xu YM; Chen XC; Ping H; Chen ZH; Zeng FQ
APMIS; 2006 Dec; 114(12):893-8. PubMed ID: 17207090
[TBL] [Abstract][Full Text] [Related]
34. Immunoreactivity of ubiquitin in human prostate gland.
Bataineh ZM; Habbal O
Neuro Endocrinol Lett; 2006 Aug; 27(4):517-22. PubMed ID: 16892003
[TBL] [Abstract][Full Text] [Related]
35. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.
Zhong WD; Han ZD; He HC; Bi XC; Dai QS; Zhu G; Ye YK; Liang YX; Qin WJ; Zhang Z; Zeng GH; Chen ZN
Oncology; 2008; 75(3-4):230-6. PubMed ID: 18852494
[TBL] [Abstract][Full Text] [Related]
36. pS2 (TFF1) expression in prostate carcinoma: correlation with steroid receptor status.
Abdou AG; Aiad HA; Sultan SM
APMIS; 2008 Nov; 116(11):961-71. PubMed ID: 19132993
[TBL] [Abstract][Full Text] [Related]
37. Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone.
Leav I; McNeal JE; Ho SM; Jiang Z
Hum Pathol; 2003 Mar; 34(3):228-33. PubMed ID: 12673556
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma.
Ricote M; García-Tuñón I; Bethencourt FR; Fraile B; Paniagua R; Royuela M
Cancer; 2004 Apr; 100(7):1388-96. PubMed ID: 15042672
[TBL] [Abstract][Full Text] [Related]
39. Genetic alterations and changes in expression of histone demethylases in prostate cancer.
Suikki HE; Kujala PM; Tammela TL; van Weerden WM; Vessella RL; Visakorpi T
Prostate; 2010 Jun; 70(8):889-98. PubMed ID: 20127736
[TBL] [Abstract][Full Text] [Related]
40. Expression of hepatocyte growth factor activator inhibitor-1 (HAI-1) gene in prostate cancer: clinical and biological significance.
Hu C; Jiang N; Wang G; Zheng J; Yang W; Yang J
J BUON; 2014; 19(1):215-20. PubMed ID: 24659667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
